-
Mashup Score: 3Treating AFib patients with TAVR still linked to elevated risks - 14 day(s) ago
While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15Readmissions after next-day discharge following transcatheter aortic valve implantation - 14 day(s) ago
Multicentre registry study evaluating the safety of next-day discharge after transcatheter aortic valve implantation with different transcatheter heart valves.
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet-
Great study led by @RodrigoBagur on next day discharge post #TAVR. In line with prior smaller studies including our own led by our former fellow Yasu Ichibori this study helps solidify the overall safety of this practice. @SakataYasushi https://t.co/kv3x3CM4G1
-
-
Mashup Score: 7
The TCW trial is the first trial to compare percutaneous treatment versus surgical treatment in patients with severe aortic stenosis and complex coronary artery disease, showing favourable primary endpoint and mortality outcomes with percutaneous treatment.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet-
Just published in The Lancet: in the TCW randomized trial, TAVR plus FFR-guided PCR proved better than SAVR plus CABG in patients with severe aortic stenosis and concomitant multivessel CAD https://t.co/Lf3R3jfEuE #TAVR @TheLancet https://t.co/zfNK04OcbJ
-
-
Mashup Score: 2
Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Off-label #TAVR for native aortic regurgitation linked to much worse outcomes @EdwardsLifesci @JenaValve @JCMedicalInc @ACCinTouch @JACCjournals @ACCmediacenter https://t.co/qtSXbnanqr
-
-
Mashup Score: 2
Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Off-label #TAVR for native aortic regurgitation linked to much worse outcomes @EdwardsLifesci @JenaValve @JCMedicalInc @ACCinTouch @JACCjournals @ACCmediacenter https://t.co/qtSXbnanqr
-
-
Mashup Score: 1Q&A: How supra-annular, self-expanding TAVR valves open up options for future interventions - 26 day(s) ago
TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.
Source: cardiovascularbusiness.comCategories: General Medicine News, Cardiology News and JournTweet-
Q&A: How supra-annular, self-expanding #TAVR valves open up options for future interventions @MDT_StructHeart @Medtronic https://t.co/xqCNvw4fMg
-
-
Mashup Score: 0TAVR technology keeps evolving, improving outcomes without compromising valve performance - 27 day(s) ago
TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
#TAVR technology keeps evolving, improving outcomes without compromising valve performance @MDT_StructHeart @Medtronic https://t.co/g3CJruLC8A
-
-
Mashup Score: 11Transcatheter Aortic Valve Replacement Explant in the Setting of a Porcelain Aorta: - 1 month(s) ago
AbstractPorcelain aorta describes circumferential calcification in the ascending aorta that may extend through the aortic arch. This is commonly observed in patients with a history of mediastinal r…
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
https://t.co/BhqEnpvJuX Here's a technically challenging case describing surgical management of a 52y/o ♀️ w/ severe mitral valve stenosis, porcelain aorta, & patient prosthesis mismatch from previously deployed #TAVR using right axillary arterial canulation & hypothermic… https://t.co/CfLzlD5j0Z https://t.co/ELKwpNoN5o
-
-
Mashup Score: 0Treating younger patients with TAVR increases risk of death - 1 month(s) ago
Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely.
Source: cardiovascularbusiness.comCategories: General Medicine News, Cardiology News and JournTweet-
Treating younger patients with #TAVR increases risk of death, rehospitalization @JAMACardio @MCoylewright https://t.co/QJVfgCJPTR
-
-
Mashup Score: 10ACURATE neo2 vs. Approved TAVR Devices in All-Risk Patients With Severe AS - American College of Cardiology - 2 month(s) ago
Anthony A. Bavry, M.D., M.P.H., FACC
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet-
Among patients w/ severe AS, ACURATE IDE trial failed to demonstrate that Acurate neo2 valve was noninferior to a commercially available valve. Mortality, stroke & rehospitalization tended to be higher in the Acurate neo2 group vs conventional #TAVR group https://t.co/jJURGh56FK… https://t.co/Y9Iujbyczq https://t.co/yHVTN8tsnz
-
Treating AFib patients with #TAVR still linked to elevated risks @SCC_CCS https://t.co/BQDJGHyV6B